CG MEDTECH, DIAGNOSTICS AND DIGITAL HEALTH & SERVICES FORUM - PULMONX CORP

Financial Performance:

• Reported first year-over-year revenue growth following declines in Q4, Q1, and Q2; Q3 revenue beat consensus by ~$1M.
• Full-year revenue guidance reiterated at $90M–$92M, implying ~10% growth at the midpoint and double-digit growth for the year-end exit.
• Cash burn reduced by ~30% to $22M for 2026 (down from $32M in 2025) after cutting ~10% of recurring costs.
• Maintains gross margins at or above 75%, driven by supply chain efficiencies and overhead absorption, despite planned China sales.
• Current cash balance is ~$53M; management identifies $120M annualized revenue as the threshold for cash-flow breakeven.
• Debt refinanced $40M due in 2026 to a 5-year interest-only facility maturing in 2031, with an additional $20M undrawn capital buffer.

Guidance and Future Outlook:

• Q4 revenue guidance set at $23.8M–$25.8M, representing 5%–14% year-over-year growth.
• Long-term goal is sustained double-digit revenue growth once the U.S. sales force fully matures.
• 2027 consensus estimate is ~$99M; company remains committed to this growth trajectory pending sales force execution.
• 2027 outlook includes a limited commercial launch of AirSeal in Europe (non-US markets).
• US commercialization of AirSeal is projected roughly two years post-pivotal study enrollment completion, with material revenue expected in 2028.
• China shipments are expected to resume in early 2027 following regulatory renewal and distributor onboarding.

Business Segments and Product Lines:

• Zephyr Valve: Core product for severe emphysema; facing challenges with ~20% of patients ineligible due to collateral ventilation.
• AirSeal (Pipeline): Next-generation polymeric foam product designed to seal fissure defects, converting ~75% of collateral ventilation-positive patients into valve candidates.
• China: Represents ~2% of global revenue; registration renewed, with delisting process to be completed by year-end and shipments restarting early next year.
• Cost Structure: Re-aligned to 2023 levels, eliminating overspending relative to revenue; one-time cost reduction achieved to stabilize the balance sheet.

Market and Competitive Landscape:

• Market opportunity remains large with no new disruptive competitive threats or reimbursement changes identified.
• Addresses a critical unmet need for severe emphysema patients exhausted of other medical or surgical options.
• China Market: Previously contributed to "wacky comps" due to low volume; now restarting with modest expected impact on overall revenue mix.
• Competitive positioning relies on clinical efficacy and expanding the treatable patient population via AirSeal technology.

Risks and Challenges:

• Sales Force Turnover: Experienced ~50% turnover in the U.S. sales force in 2025; new hires require 6–9 months to reach full productivity.
• Revenue Variability: Guidance range variance is primarily driven by the ramp-up speed of new sales personnel and Q4 seasonality.
• Pipeline Execution: AirSeal FDA approval timeline is approximately two years post-enrollment, presenting execution risk.
• Gross Margin Drag: Potential margin pressure from China sales and new AirSeal launch, though management expects to maintain >75% margins.
• Cash Flow: Dependency on current capital runway to reach $120M revenue breakeven point without immediate new funding.

Management Commentary and Tone:

• Turnaround Status: Management views financial stabilization (cost cuts, debt refinancing) as largely complete; the third pillar (sales growth) is "a work in progress" but showing progress.
• Strategic Focus: Adopted a "back-to-basics" approach, narrowing sales strategy to clinical champions, treating centers, and administrative support.
• Tone: Cautiously optimistic and data-driven; management emphasizes "show-me" results over forward-looking verbal commitments, stating "we want results to speak for themselves."
• Leadership: COO/CFO Derek Sung has assumed non-commercial operations (R&D, regulatory, manufacturing) to allow CEO Glenn to focus exclusively on the commercial turnaround.

Analyst Questions and Answers:

• Q: What drove the sales force turnaround? A: Addressed comp plan changes, organizational shuffling, hiring new managers, and refilling territories; morale is improving.
• Q: How will AirSeal impact the Total Addressable Market (TAM)? A: Expected to have a "halo effect" by ensuring 95% of referred patients receive treatment (vs. 80% currently), improving referral patterns.
• Q: Will OpEx increase if revenue accelerates? A: No immediate increases planned; cost structure is viewed as lean enough to support growth, with OpEx expected to grow only in low single digits.
• Q: What constitutes proof of turnaround in 12 months? A: Management expects to point to concrete financial numbers (sustained growth and profitability) as the primary indicator.

Other Key Points:

• AirSeal is described as a "market expander" that converts patients previously deemed ineligible for Zephyr valves due to anatomical constraints.
• The company has over 75% gross margins and is a $90M+ revenue entity.
• China's return is anticipated to be slightly accretive to the bottom line despite lower margins, with no significant drag on overall margin targets.
• The "perfect storm" of turnover in 2025 was attributed to role changes, compensation adjustments, and management style shifts, all of which have been rectified.